# 动力抑制

[◀返回](./home.md)

**动力抑制**（也被称为**意志减退**或**动机缺乏**）[\[1\]](#cite_note-FervahaTakeuchi2015-1) 被定义为开始或坚持目标导向行为的欲望减少啦[\[2\]](#cite_note-LeeJung2015-2)[\[3\]](#cite_note-BarchDowd2010-3)。动力抑制让一个人无法把一个行动的奖赏价值维持到不确定的未来；这包括那些被认为有挑战性或不愉快的任务，比如工作、学习、打扫卫生和做家务。在程度比较高的时候，动力抑制会导致一个人失去参与任何活动的欲望，甚至包括那些通常被认为是有趣或有回报的活动呢。如果这种效应以高强度持续很长时间，可能会导致严重的无聊状态，甚至轻微的抑郁哦。

动力抑制通常还伴随着其他效应，比如[镇静](/药效/镇静.md)和[思维减速](/药效/思维减速.md)。它最常在急性[给药](/文档/给药剂量.md)的[抗精神病药](/文档/药物分类/抗精神病药.md)影响下出现，比如[喹硫平](/药物/喹硫平.md)、[氟哌啶醇](/药物/氟哌啶醇.md)和[利培酮](/药物/利培酮.md)[\[4\]](#cite_note-ArtaloytiaArango2006-4)[\[5\]](#cite_note-SaeediRemington2006-5)。不过要注意的是，长期服用任何[剂量](/文档/给药剂量.md)的[抗精神病药](/文档/药物分类/抗精神病药.md)治疗并不会导致这种效应哦[\[1\]](#cite_note-FervahaTakeuchi2015-1)。它也可能发生在[严重](/文档/药物剂量分类.md#heavy)剂量的[大麻类](/文档/药物分类/大麻类.md)物质[\[6\]](#cite_note-LawnFreeman2016-6)和[苯二氮卓类物质](/文档/药物分类/苯二氮卓类物质.md)的影响下，作为长期使用SSRI类药物的后果[\[7\]](#cite_note-Starcevic2014-7)，或者在[兴奋剂](/文档/药物分类/兴奋剂.md)的[药效褪去](/文档/药效时长.md#Offset)期间，以及几乎任何化合物的[药物戒断反应](/文档/药物戒断反应.md)期间出现呢。

### 体验报告

在我们的[体验报告](/报告/psychounautwiki/)中，描述了这种效应的轶事报告包括：

*   [Experience:100-350mg - Phenylpiracetam in daily life](/报告/psychounautwiki/Experience:100-350mg_-_Phenylpiracetam_in_daily_life)
*   [Experience:FMA (37.5 mg, oral) - Never been this productive in my life](/报告/psychounautwiki/Experience:FMA_(37.5_mg,_oral)_-_Never_been_this_productive_in_my_life)
*   [Experience:Marijuana Withdrawal](/报告/psychounautwiki/Experience:Marijuana_Withdrawal)
*   [Experience:~150mg MDA(oral) - a case of mistaken identity](/报告/psychounautwiki/Experience:~150mg_MDA(oral)_-_a_case_of_mistaken_identity)

### 另见

*   [负责任的用药索引页](/文档/负责任的用药索引页.md)
*   [主观效应索引](/文档/科学信息索引页.md)
*   [动机增强](/药效/动机增强.md)
*   [苯海拉明](/药物/苯海拉明.md)
*   [迷幻剂 - 主观效应](/文档/药物分类/迷幻剂.md#Subjective_effects)
*   [解离剂 - 主观效应](/文档/药物分类/解离剂.md#Subjective_effects)
*   [谵妄剂 - 主观效应](/文档/药物分类/谵妄剂.md#Subjective_effects)

### 外部链接

*   [快感缺失 (维基百科)](https://en.wikipedia.org/wiki/Anhedonia)
*   [情感淡漠 (维基百科)](https://en.wikipedia.org/wiki/Apathy)
*   [无聊 (维基百科)](https://en.wikipedia.org/wiki/Boredom)
*   [嗜睡 (维基百科)](https://en.wikipedia.org/wiki/Lethargy)

### 参考文献

1.  ↑ [1.0](#cite_ref-FervahaTakeuchi2015_1-0) [1.1](#cite_ref-FervahaTakeuchi2015_1-1) Fervaha, Gagan; Takeuchi, Hiroyoshi; Lee, Jimmy; Foussias, George; Fletcher, Paul J; Agid, Ofer; Remington, Gary (2015). "Antipsychotics and Amotivation". *Neuropsychopharmacology*. **40** (6): 1539–1548. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1038/npp.2015.3](//doi.org/10.1038%2Fnpp.2015.3). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0893-133X](//www.worldcat.org/issn/0893-133X).
2.  [↑](#cite_ref-LeeJung2015_2-0) Lee, Jung; Jung, Suwon; Park, Il; Kim, Jae-Jin (2015). "Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System". *Current Neuropharmacology*. **13** (6): 750–759. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.2174/1570159X13666150612230333](//doi.org/10.2174%2F1570159X13666150612230333). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1570-159X](//www.worldcat.org/issn/1570-159X).
3.  [↑](#cite_ref-BarchDowd2010_3-0) Barch, D. M.; Dowd, E. C. (2010). "Goal Representations and Motivational Drive in Schizophrenia: The Role of Prefrontal-Striatal Interactions". *Schizophrenia Bulletin*. **36** (5): 919–934. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1093/schbul/sbq068](//doi.org/10.1093%2Fschbul%2Fsbq068). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0586-7614](//www.worldcat.org/issn/0586-7614).
4.  [↑](#cite_ref-ArtaloytiaArango2006_4-0) Artaloytia, Juan Francisco; Arango, Celso; Lahti, Adrienne; Sanz, Javier; Pascual, Ana; Cubero, Pedro; Prieto, David; Palomo, Tomás (2006). "Negative Signs and Symptoms Secondary to Antipsychotics: A Double-Blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, and Risperidone in Healthy Volunteers". *American Journal of Psychiatry*. **163** (3): 488–493. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1176/appi.ajp.163.3.488](//doi.org/10.1176%2Fappi.ajp.163.3.488). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0002-953X](//www.worldcat.org/issn/0002-953X).
5.  [↑](#cite_ref-SaeediRemington2006_5-0) Saeedi, H; Remington, G; Christensen, B (2006). "Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood". *Schizophrenia Research*. **85** (1-3): 222–231. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.schres.2006.03.033](//doi.org/10.1016%2Fj.schres.2006.03.033). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0920-9964](//www.worldcat.org/issn/0920-9964).
6.  [↑](#cite_ref-LawnFreeman2016_6-0) Lawn, Will; Freeman, Tom P; Pope, Rebecca A; Joye, Alyssa; Harvey, Lisa; Hindocha, Chandni; Mokrysz, Claire; Moss, Abigail; Wall, Matthew B; Bloomfield, Michael AP; Das, Ravi K; Morgan, Celia JA; Nutt, David J; Curran, H Valerie (2016). "Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses". *Psychopharmacology*. **233** (19-20): 3537–3552. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1007/s00213-016-4383-x](//doi.org/10.1007%2Fs00213-016-4383-x). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0033-3158](//www.worldcat.org/issn/0033-3158).
7.  [↑](#cite_ref-Starcevic2014_7-0) Starcevic, Vladan (2014). "The reappraisal of benzodiazepines in the treatment of anxiety and related disorders". *Expert Review of Neurotherapeutics*. **14** (11): 1275–1286. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1586/14737175.2014.963057](//doi.org/10.1586%2F14737175.2014.963057). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1473-7175](//www.worldcat.org/issn/1473-7175).
